Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer

07-Mar-2016 - Merck, Pfizer and Verastem announced that they have entered into an agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s VS-6063, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ...

Merck, Pfizer and Syndax Announce Collaboration

06-Jan-2016 - Merck, Pfizer and Syndax Pharmaceuticals, Inc. announced that they have entered into a collaboration agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax’s entinostat, an investigational oral small molecule that targets ...

Merck Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer

08-Dec-2015 - Merck announced that it is not planning to file for approval of evofosfamide in advanced soft tissue sarcoma and advanced pancreatic adenocarcinoma. The decision was made in light of the results from two Phase III studies of evofosfamide in combination with chemotherapy in these two types of ...

Merck and Pfizer Receive Positive Opinion from EMA Committee

26-Nov-2015 - Merck and Pfizer announced that the European Medicines Agency (EMA)’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for Orphan Drug designation (ODD) for avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, pending an official decision by ...

Merck and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab

20-Nov-2015 - Merck and Pfizer announced that the US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after ...

Merck and Pfizer Collaborate with Dako

Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

28-Sep-2015 - As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab, an investigational immune checkpoint inhibitor, the companies have announced that they have a collaboration agreement in place with Dako, an Agilent Technologies company, for the ...